N-acetylcysteine prevents rotenone-induced Parkinson's disease in rat: An investigation into the interaction of parkin and Drp1 proteins

Brain Research Bulletin

Volumn 113, Issue , 2015, Pages 34-40

  Rahimmi, Arman ^a,b   Khosrobakhsh, Farnoosh ^a   Izadpanah, Esmael ^b   Moloudi, Mohammad Raman ^b   Hassanzadeh, Kambiz ^b  

^a UNIVERSITY OF KURDISTAN   (Iran)

^b KURDISTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Drp1; N acetylcysteine; Parkin; Parkinson's disease; Rotenone

Indexed keywords

ACETYLCYSTEINE; DOPAMINE; DYNAMIN RELATED PROTEIN 1; PARKIN; PEPTIDES AND PROTEINS; ROTENONE; UNCLASSIFIED DRUG; DRP1 PROTEIN, RAT; DYNAMIN; PROTEIN BINDING; UBIQUITIN PROTEIN LIGASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; EXPERIMENTAL BEHAVIORAL TEST; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MUSCLE STRENGTH; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; DRUG INTERACTION; METABOLISM; OXIDATIVE STRESS; PARKINSONIAN DISORDERS; RANDOMIZATION; ROTAROD TEST; WISTAR RAT;

ACETYLCYSTEINE; ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINERGIC NEURONS; DRUG INTERACTIONS; DYNAMINS; MALE; OXIDATIVE STRESS; PARKINSONIAN DISORDERS; PROTEIN BINDING; RANDOM ALLOCATION; RATS; RATS, WISTAR; ROTAROD PERFORMANCE TEST; ROTENONE; SUBSTANTIA NIGRA; UBIQUITIN-PROTEIN LIGASES;

EID: 84924336402     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2015.02.007     Document Type: Article

References (32)

1. Anichtchik O.V., Rinne J.O., Kalimo H., Panula P. An altered histaminergic innervation of the substantia nigra in Parkinson's disease. Exp. Neurol. 2000, 163:20-30.
2. Cannon J.R., Tapias V., Na H.M., Honick A.S., Drolet R.E., Greenamyre J.T. A highly reproducible rotenone model of Parkinson's disease. Neurobiol. Dis. 2009, 34:279-290.
3. Chen C.M., Yin M.C., Hsu C.C., Liu T.C. Antioxidative and anti-inflammatory effects of four cysteine-containing agents in striatum of MPTP-treated mice. Nutrition 2007, 23:589-597.
4. Clark J., Clore E.L., Zheng K., Adame A., Masliah E., Simon D.K. Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing mice. PLoS One 2010, 5:e12333.
5. Darios F., Corti O., Lucking C.B., Hampe C., Muriel M.P., Abbas N., Gu W.J., Hirsch E.C., Rooney T., Ruberg M., Brice A. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum. Mol. Genet. 2003, 12:517-526.
6. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
7. Dringen R. Metabolism and functions of glutathione in brain. Prog. Neurobiol. 2000, 62:649-671.
8. Fleming S.M., Zhu C., Fernagut P.O., Mehta A., DiCarlo C.D., Seaman R.L., Chesselet M.F. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Exp. Neurol. 2004, 187:418-429.
9. Iancu R., Mohapel P., Brundin P., Paul G. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav. Brain Res. 2005, 162:1-10.
10. Jiang H., Ren Y., Zhao J., Feng J. Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. Hum. Mol. Genet. 2004, 13:1745-1754.
11. Lin C.H., Kuo S.C., Huang L.J., Gean P.W. Neuroprotective effect of N-acetylcysteine on neuronal apoptosis induced by a synthetic gingerdione compound: involvement of ERK and p38 phosphorylation. J. Neurosci. Res. 2006, 84:1485-1494.
12. Mata I.F., Lockhart P.J., Farrer M.J. Parkin genetics: one model for Parkinson's disease. Hum. Mol. Genet. 2004, 13(Spec No 1):R127-R133.
13. Meister A., Anderson M.E. Glutathione. Annu. Rev. Biochem. 1983, 52:711-760.
14. Oien D.B., Osterhaus G.L., Latif S.A., Pinkston J.W., Fulks J., Johnson M., Fowler S.C., Moskovitz J. MsrA knockout mouse exhibits abnormal behavior and brain dopamine levels. Free Radic. Biol. Med. 2008, 45:193-200.
15. Panov A., Dikalov S., Shalbuyeva N., Taylor G., Sherer T., Greenamyre J.T. Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication. J. Biol. Chem. 2005, 280:42026-42035.
16. Phinney A.L., Andringa G., Bol J.G., Wolters E., van Muiswinkel F.L., van Dam A.M., Drukarch B. Enhanced sensitivity of dopaminergic neurons to rotenone-induced toxicity with aging. Parkinsonism Relat. Disord. 2006, 12:228-238.
17. Qi X., Qvit N., Su Y.C., Mochly-Rosen D. A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity. J. Cell Sci. 2013, 126:789-802.
18. Rahimmi A., Khosrobakhsh F., Izadpanah E., Hassanzadeh K. Induction of Parkinson's disease model in rat by rotenone. J. Isfahan Med. Sch. 2014, 32(296):1250-1258.
19. Rogers D.C., Fisher E.M., Brown S.D., Peters J., Hunter A.J., Martin J.E. Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment. Mamm. Genome 1997, 8:711-713.
20. Scalley R.D., Conner C.S. Acetaminophen poisoning: a case report of the use of acetylcysteine. Am. J. Hosp. Pharm. 1978, 35:964-967.
21. Sherer T.B., Betarbet R., Stout A.K., Lund S., Baptista M., Panov A.V., Cookson M.R., Greenamyre J.T. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J. Neurosci. 2002, 22:7006-7015.
22. Sherer T.B., Betarbet R., Testa C.M., Seo B.B., Richardson J.R., Kim J.H., Miller G.W., Yagi T., Matsuno-Yagi A., Greenamyre J.T. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 2003, 23:10756-10764.
23. Smeyne M., Smeyne R.J. Glutathione metabolism and Parkinson's disease. Free Radic. Biol. Med. 2013, 62:13-25.
24. Sonia Angeline M., Chaterjee P., Anand K., Ambasta R.K., Kumar P. Rotenone-induced parkinsonism elicits behavioral impairments and differential expression of parkin, heat shock proteins and caspases in the rat. Neuroscience 2012, 220:291-301.
25. Soto-Otero R., Mendez-Alvarez E., Sanchez-Iglesias S., Zubkov F.I., Voskressensky L.G., Varlamov A.V., de Candia M., Altomare C. Inhibition of 6-hydroxydopamine-induced oxidative damage by 4,5-dihydro-3H-2-benzazepine N-oxides. Biochem. Pharmacol. 2008, 75:1526-1537.
26. Stey C., Steurer J., Bachmann S., Medici T.C., Tramer M.R. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur. Respir. J. 2000, 16:253-262.
27. Urbach Y.K., Bode F.J., Nguyen H.P., Riess O., von Horsten S. Neurobehavioral tests in rat models of degenerative brain diseases. Methods Mol. Biol. 2010, 597:333-356.
28. Vandeputte C., Taymans J.-M., Casteels C., Coun F., Ni Y., Van Laere K., Baekelandt V. Automated quantitative gait analysis in animal models of movement disorders. BMC Neurosci. 2010, 11:1-11.
29. Wang C., Ko H.S., Thomas B., Tsang F., Chew K.C., Tay S.P., Ho M.W., Lim T.M., Soong T.W., Pletnikova O., Troncoso J., Dawson V.L., Dawson T.M., Lim K.L. Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. Hum. Mol. Genet. 2005, 14:3885-3897.
30. Wang H., Song P., Du L., Tian W., Yue W., Liu M., Li D., Wang B., Zhu Y., Cao C., Zhou J., Chen Q. Parkin ubiquitinates Drp1 for proteasome-dependent degradation: implication of dysregulated mitochondrial dynamics in Parkinson disease. J. Biol. Chem. 2011, 286:11649-11658.
31. West A.B., Maraganore D., Crook J., Lesnick T., Lockhart P.J., Wilkes K.M., Kapatos G., Hardy J.A., Farrer M.J. Functional association of the parkin gene promoter with idiopathic Parkinson's disease. Hum. Mol. Genet. 2002, 11:2787-2792.
32. Xiong N., Xiong J., Khare G., Chen C., Huang J., Zhao Y., Zhang Z., Qiao X., Feng Y., Reesaul H., Zhang Y., Sun S., Lin Z., Wang T. Edaravone guards dopamine neurons in a rotenone model for Parkinson's disease. PLoS One 2011, 6:e20677.